|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms E Walmsley
|
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 April 2017.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.4042
|
448.783
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr R G Connor
|
|
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 April 2017.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.4042
|
403.744
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr L Debruyne
|
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 April 2017.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.4042
|
1,079.517
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr S Dingemans
|
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 April 2017.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.4042
|
871.935
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr S A Hussain
|
|
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 April 2017.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.4042
|
1,375.318
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr D S Redfern
|
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 April 2017.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.4042
|
1,471.854
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms C Thomas
|
|
|
b)
|
Position/status
|
SVP, HR
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 April 2017.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.4042
|
478.351
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr P C Thomson
|
|
|
b)
|
Position/status
|
President,
Global Affairs
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 April 2017.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.4042
|
690.515
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Dr P J T Vallance
|
|
|
b)
|
Position/status
|
President, R&D
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 April 2017.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.4042
|
2,767.208
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mrs K Thomson
|
|
|
b)
|
Position/status
|
PCA of Mr P C Thomson (President, Global Affairs)
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 April 2017.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.4042
|
130.423
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: April
19, 2017
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|